SecBot SecBot
Insider Cluster (2 insiders) ·Filed Mar 13, 2026

CNTA

Centessa Pharmaceuticals plc
BEARISH
Impact 7/10
Horizondays Processed8mo ago
Insider cluster: 2 insiders, $4.4M total
Actionable Insight ▼ Bearish

Monitor for upcoming earnings or pipeline updates; such concentrated C-suite selling often precedes negative news or reflects valuation concerns. Watch for follow-on selling or lack of buybacks.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.29
T+0 close · Mar 13, 2026 · via day close
Latest settled
+40.30%
T+60 · $39.69
Vs SPY
+31.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 16 $28.29entry
  2. T+1 · 8mo ago +2.33%α +2.07% · $28.95
  3. T+5 · 8mo ago −8.31%α −6.27% · $25.94
  4. T+20 · 7mo ago +39.94%α +36.14% · $39.59
  5. T+60 · 5mo ago +40.30%α +31.87% · $39.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from Chief People Officer Karen Anderson's open-market sales of 215,922 shares. These sales followed derivative exercises and represent a material insider divestment.

Key Financial Metrics

Direction
selling
Total Value
$7.2M
Insiders
2

Key Facts

  • Chief People Officer Karen Anderson sold 215,922 shares for $5.65M in open-market transactions at ~$26.15 per share
  • Anderson also exercised derivatives for 407,244 shares (some at $4.01, others at $0), with total economic value of $816,524.22
  • Chief Business Officer Gregory Weinhoff sold 61,253 shares for $1.6M
  • Total open-market sales by insiders: $7.25M over 7 days
  • Total insider sales represent ~0.19% of $3.8B market cap, significant for a biotech

Financial Impact

$7.25M in open-market insider selling, representing 0.19% of market cap

insider sentimentshareholder dilution riskmarket confidence

Risk Factors

  • Insider selling may signal lack of confidence in near-term prospects
  • Biotech stocks are sensitive to sentiment; this level of selling could pressure share price

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (7 trades, 7d window)cluster-CNTA-1773699014839

Track record

5 reports on CNTA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +8.31% at T+5 after the Mar 13, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Jul 6, 202619w ago 15-12G Bearish 7/10 No price data
  2. Apr 17, 202630w ago PREM14A Bullish 9/10 Entry $39.51 to $39.51 · 0.00% −0.91% vs SPY
  3. Apr 13, 202631w ago DEFA14A Bullish 8/10 Entry $39.59 to $39.49 ▼ −0.25% −1.65% vs SPY
  4. Mar 13, 202635w ago Insider Cluster Bearish 7/10 Viewing Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
  5. Mar 13, 202635w ago Insider Cluster Bearish 6/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 16, 2026